0001209191-23-057972.txt : 20231208 0001209191-23-057972.hdr.sgml : 20231208 20231208172236 ACCESSION NUMBER: 0001209191-23-057972 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231206 FILED AS OF DATE: 20231208 DATE AS OF CHANGE: 20231208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gibson Christopher CENTRAL INDEX KEY: 0001856369 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 231476379 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-06 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856369 Gibson Christopher C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 1 0 0 Chief Executive Officer 0 Class A Common Stock 2023-12-06 4 C 0 10000 0.00 A 829907 D Class A Common Stock 2023-12-06 4 G 0 10000 0.00 D 819907 D Class A Common Stock 2023-12-06 4 M 0 31250 2.48 A 851157 D Class A Common Stock 2023-12-06 4 S 0 59829 7.4946 D 791328 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 813600 D Stock Option (Right to Buy) 11.40 2022-02-04 2032-02-04 Class A Common Stock 0 5436 D Stock Option (Right to Buy) 11.40 2032-02-04 Class A Common Stock 0 407676 D Stock Option (Right to Buy) 2.48 2023-12-06 4 M 0 31250 0.00 D 2030-12-30 Class A Common Stock 31250 406250 D Class B Common Stock 0.00 2023-12-06 4 C 0 10000 0.00 D Class A Common Stock 10000 6491496 D Class B Common Stock 0.00 Class A Common Stock 4000 519000 I by LAHWRAN-3 LLC Class B Common Stock 0.00 Class A Common Stock 20000 428000 I by LAHWRAN-4 LLC Class B Common Stock 0.00 Class A Common Stock 1000 119875 I by Gibson Family Trust Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 22, 2022. This transaction was executed in multiple trades at prices ranging from $7.21 to $8.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. /s/ Jonathan Golightly, attorney-in-fact 2023-12-08